The role of Src in solid and hematologic malignancies: Development of new-generation src inhibitors

Ricardo H. Alvarez, Hagop M. Kantarjian, Jorge E. Cortes

Research output: Contribution to journalReview article

Abstract

c-Src was the first protooncogene described and was among the first molecules in which tyrosine kinase activity was documented. c-Src has been defined as a common modular structure that participates in much of the crosstalk between the cytoplasmic protein tyrosine kinases and tyrosine kinase receptors. Understanding the structure and function of this important class of protein kinases and elucidating the molecular signaling events mediated by c-Src are important not only for identifying the critical pathways but also for designing new strategies to block or inhibit the action of these kinases. Despite the large amount of information available on c-Src, its precise functions in cancer remain to be elucidated. Recently, there has been renewed interest in c-Src as a molecular target for cancer therapy, and multiple c-Src inhibitors are entering clinical trials. In this review, the authors describe the function and expression of c-Src in human malignancies and the novel c-Src inhibitors and their potential applications for cancer treatment.

Original languageEnglish (US)
Pages (from-to)1918-1929
Number of pages12
JournalCancer
Volume107
Issue number8
DOIs
StatePublished - Oct 15 2006
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Protein-Tyrosine Kinases
Neoplasms
Critical Pathways
Receptor Protein-Tyrosine Kinases
Protein Kinases
Phosphotransferases
Clinical Trials
Therapeutics

Keywords

  • Solid and hematologic malignancies
  • Src inhibitors
  • Src oncogens
  • Tyrosine kinases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The role of Src in solid and hematologic malignancies : Development of new-generation src inhibitors. / Alvarez, Ricardo H.; Kantarjian, Hagop M.; Cortes, Jorge E.

In: Cancer, Vol. 107, No. 8, 15.10.2006, p. 1918-1929.

Research output: Contribution to journalReview article

Alvarez, Ricardo H. ; Kantarjian, Hagop M. ; Cortes, Jorge E. / The role of Src in solid and hematologic malignancies : Development of new-generation src inhibitors. In: Cancer. 2006 ; Vol. 107, No. 8. pp. 1918-1929.
@article{3aef057821f44879b55707e2c6d218d6,
title = "The role of Src in solid and hematologic malignancies: Development of new-generation src inhibitors",
abstract = "c-Src was the first protooncogene described and was among the first molecules in which tyrosine kinase activity was documented. c-Src has been defined as a common modular structure that participates in much of the crosstalk between the cytoplasmic protein tyrosine kinases and tyrosine kinase receptors. Understanding the structure and function of this important class of protein kinases and elucidating the molecular signaling events mediated by c-Src are important not only for identifying the critical pathways but also for designing new strategies to block or inhibit the action of these kinases. Despite the large amount of information available on c-Src, its precise functions in cancer remain to be elucidated. Recently, there has been renewed interest in c-Src as a molecular target for cancer therapy, and multiple c-Src inhibitors are entering clinical trials. In this review, the authors describe the function and expression of c-Src in human malignancies and the novel c-Src inhibitors and their potential applications for cancer treatment.",
keywords = "Solid and hematologic malignancies, Src inhibitors, Src oncogens, Tyrosine kinases",
author = "Alvarez, {Ricardo H.} and Kantarjian, {Hagop M.} and Cortes, {Jorge E.}",
year = "2006",
month = "10",
day = "15",
doi = "10.1002/cncr.22215",
language = "English (US)",
volume = "107",
pages = "1918--1929",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - The role of Src in solid and hematologic malignancies

T2 - Development of new-generation src inhibitors

AU - Alvarez, Ricardo H.

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

PY - 2006/10/15

Y1 - 2006/10/15

N2 - c-Src was the first protooncogene described and was among the first molecules in which tyrosine kinase activity was documented. c-Src has been defined as a common modular structure that participates in much of the crosstalk between the cytoplasmic protein tyrosine kinases and tyrosine kinase receptors. Understanding the structure and function of this important class of protein kinases and elucidating the molecular signaling events mediated by c-Src are important not only for identifying the critical pathways but also for designing new strategies to block or inhibit the action of these kinases. Despite the large amount of information available on c-Src, its precise functions in cancer remain to be elucidated. Recently, there has been renewed interest in c-Src as a molecular target for cancer therapy, and multiple c-Src inhibitors are entering clinical trials. In this review, the authors describe the function and expression of c-Src in human malignancies and the novel c-Src inhibitors and their potential applications for cancer treatment.

AB - c-Src was the first protooncogene described and was among the first molecules in which tyrosine kinase activity was documented. c-Src has been defined as a common modular structure that participates in much of the crosstalk between the cytoplasmic protein tyrosine kinases and tyrosine kinase receptors. Understanding the structure and function of this important class of protein kinases and elucidating the molecular signaling events mediated by c-Src are important not only for identifying the critical pathways but also for designing new strategies to block or inhibit the action of these kinases. Despite the large amount of information available on c-Src, its precise functions in cancer remain to be elucidated. Recently, there has been renewed interest in c-Src as a molecular target for cancer therapy, and multiple c-Src inhibitors are entering clinical trials. In this review, the authors describe the function and expression of c-Src in human malignancies and the novel c-Src inhibitors and their potential applications for cancer treatment.

KW - Solid and hematologic malignancies

KW - Src inhibitors

KW - Src oncogens

KW - Tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=33750076068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750076068&partnerID=8YFLogxK

U2 - 10.1002/cncr.22215

DO - 10.1002/cncr.22215

M3 - Review article

C2 - 16986126

AN - SCOPUS:33750076068

VL - 107

SP - 1918

EP - 1929

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -